Gene Therapy for Alpha 1-Antitrypsin (AAT) Deficiency

Lead Inventor:

Ronald Crystal, M.D.
Chairman of Genetic Medicine, Weill Cornell Medical College
Professor of Genetic Medicine, Weill Cornell Medical College
The Bruce Webster Professor of Internal Medicine, Weill Cornell Medical College
Professor of Medicine, Weill Cornell Medical College

Business Development Contact:
Brian Kelly
Director, Technology Licensing
(646) 962-7041
bjk44@cornell.edu
### Background & Unmet Need

- **Alpha 1-antitrypsin (AAT) deficiency** is a hereditary disorder characterized by low serum levels of functional AAT, and is associated with early development of panacinar emphysema.
- AAT deficiency affects ~90 K patients in the U.S., and is caused by mutation in the SERPINA1 gene.
- AAT inhibits serine proteases, including neutrophil elastase, protecting the lung from proteolytic destruction.
- The current SOC for AAT deficiency is weekly infusions of purified AAT from pooled human plasma.
- While AAT augmentation therapy is safe and reduces the rate of lung destruction, it requires burdensome weekly parenteral infusions and carries risks of allergic reactions and viral contamination of human plasma-derived products.
- **Unmet Need**: Therapeutic strategy to augment AAT levels in a safe and convenient format.

### Technology Overview

- **The Technology**: AAV8 gene transfer vector coding for an oxidant-resistant form of AAT for the treatment of AAT deficiency.
- The oxidation-resistant AAT (A213/V351/L358) maintains antiprotease activity under oxidant stress compared to wild-type and other engineered variants.
- **PoC Data**: A single dose of 8/AVL afforded sustained serum AAT levels, in both male and female mice, with similar absolute AAT levels for both IV and IPL delivery.
- However, IPL delivery provided a significantly higher lung epithelial lining fluid (ELF) to serum ratio of AAT than IV delivery, suggesting IPL is the preferred delivery route.
- Mice administered the 8/AVL vector retain anti-NE activity in the ELF 24 weeks after treatment, whereas mice receiving the WT 8/AMM vector display no anti-NE activity under oxidizing conditions.

### Inventors:
- Ronald Crystal
- Stephen Kaminsky
- Jonathan Rosenberg
- Katie Stiles
- Dolan Sondhi
- Meredith Sosulski

### Patents:
- US Application Filed
- EP Application Filed

### Publications:

### Biz Dev Contact:
- Brian Kelly
  - (646) 962-7041
  - bjk44@cornell.edu

### Cornell Reference:
- D-7690
Gene Therapy for Alpha 1-Antitrypsin (AAT) Deficiency

**Technology Applications**

- One-time treatment of AAT deficiency
- Provides a general strategy for optimizing gene therapy for other diseases associated with enzymatic deficiency

**Technology Advantages**

- The modified AAT protein is highly resistant to oxidant stress and less susceptible to potential anti-AAT immunity than the wild-type protein
- Single dose treatment significantly improves patient quality of life compared to weekly infusions

**Supporting Data / Figures**

**Figure 1:** Comparison of in vivo-produced human AAT-modified variants’ ability to inhibit neutrophil elastase (NE) and cathepsin G activity. 8/AMM expressed the WT enzyme. 8/AVL was selected for further characterization due to best performance under oxidizing conditions.

Inventors:
- Ronald Crystal
- Stephen Kaminsky
- Jonathan Rosenberg
- Katie Stiles
- Doian Sondhi
- Meredith Sosulski

Patents:
- US Application Filed
- EP Application Filed

Publications:
- Sosulski et al. _JCI Insight_. 2020.

Biz Dev Contact:
- Brian Kelly
  (646) 962-7041
  bjk44@cornell.edu

Cornell Reference:
D-7690
Supporting Data / Figures

**Figure 2:** The 8/AVL gene therapy delivers durable hAAT levels equivalent to the 8/AMM WT vector in both male and female mice, with similar performance absolute levels of hAAT for both IV and IPL administration.

**Figure 3:** Mice administered the 8/AVL vector retain anti-NE activity in the lung epithelial lining fluid (ELF) 24 weeks after treatment, whereas mice receiving the WT 8/AMM vector display no anti-NE activity under oxidizing conditions.